Home > Insider Trading > Filing (0001062993-23-018574)

Filing Details

Accession Number:: 0001062993-23-018574
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-09-28 15:45:22
Reporting Period:: 2023-09-26

Accepted Time:: 2023-09-28 15:45:22
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1484565	Soleno Therapeutics Inc	SLNO	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1164426	Joseph Edelman	51 Astor Place, 10Th Floor New York NY 10003	No	No	Yes	No
1224962	Perceptive Advisors Llc	51 Astor Place, 10Th Floor New York NY 10003	No	No	Yes	No
1249675	Ltd Fund Master Sciences Life Perceptive	51 Astor Place, 10Th Floor New York NY 10003	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-09-26	5,703	$7.65	2,213,456	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	13,687	$8.30	2,227,143	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	5,419	$9.52	2,232,562	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	37,911	$11.05	2,270,473	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	77,837	$11.81	2,348,310	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	42,838	$12.84	2,391,148	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	30,511	$13.92	2,421,659	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	3,326	$14.61	2,424,985	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	27,769	$16.00	2,452,754	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	75,477	$17.28	2,528,231	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	52,691	$18.24	2,580,922	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	88,685	$19.11	2,669,607	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	117,996	$20.03	2,787,603	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-26	36,939	$21.00	2,824,542	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2023-09-28	250,000	$20.00	3,074,542	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Pre-funded warrants (right to buy)	Acquisiton	2023-09-28	250,000	$19.99	250,000	$0.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
250,000	2023-10-02		No	4	P	Indirect

Footnotes

The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
The price reported is a weighted average price. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported.
These shares were purchased in multiple transactions at prices ranging from $6.95 to $7.87, inclusive.
These shares were purchased in multiple transactions at prices ranging from $8.00 to $8.89, inclusive.
These shares were purchased in multiple transactions at prices ranging from $9.32 to $9.73, inclusive.
These shares were purchased in multiple transactions at prices ranging from $10.39 to $11.38, inclusive.
These shares were purchased in multiple transactions at prices ranging from $11.39 to $12.40, inclusive.
These shares were purchased in multiple transactions at prices ranging from $12.41 to $13.40, inclusive.
These shares were purchased in multiple transactions at prices ranging from $13.42 to $14.41, inclusive.
These shares were purchased in multiple transactions at prices ranging from $14.42 to $15.00, inclusive.
These shares were purchased in multiple transactions at prices ranging from $15.66 to $16.50, inclusive.
These shares were purchased in multiple transactions at prices ranging from $16.70 to $17.695, inclusive.
These shares were purchased in multiple transactions at prices ranging from $17.70 to $18.69, inclusive.
These shares were purchased in multiple transactions at prices ranging from $18.70 to $19.69, inclusive.
These shares were purchased in multiple transactions at prices ranging from $19.70 to $20.69, inclusive.
These shares were purchased in multiple transactions at prices ranging from $20.70 to $21.40, inclusive.
Purchased in the Issuer's registered public offering scheduled to close on October 2, 2023.
Represents pre-funded warrants purchased in the Issuer's private placement scheduled to close on October 2, 2023. The pre-funded warrants may not be exercised if the holder together with its affiliates would beneficially own more than 9.99% of the Issuer's outstanding shares of common stock after giving effect to the exercise.